scPharmaceuticals Inc. (SCPH): Price and Financial Metrics


scPharmaceuticals Inc. (SCPH)

Today's Latest Price: $8.74 USD

0.05 (-0.57%)

Updated Dec 4 4:00pm

Add SCPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SCPH Stock Price Chart Interactive Chart >

Price chart for SCPH

SCPH Price/Volume Stats

Current price $8.74 52-week high $11.99
Prev. close $8.79 52-week low $4.01
Day low $8.61 Volume 76,900
Day high $9.01 Avg. volume 84,640
50-day MA $8.61 Dividend yield N/A
200-day MA $8.37 Market Cap 238.79M

scPharmaceuticals Inc. (SCPH) Company Bio


scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.


SCPH Latest News Stream


Event/Time News Detail
Loading, please wait...

SCPH Latest Social Stream


Loading social stream, please wait...

View Full SCPH Social Stream

Latest SCPH News From Around the Web

Below are the latest news stories about scPharmaceuticals Inc that investors may wish to consider to help them evaluate SCPH as an investment opportunity.

scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals to host a KOL call on an investigational drug for the outpatient treatment of congestion in patients with heart failure.

Business Wire | September 17, 2020

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals announced it will present at the virtual HC Wainwright Annual Global Investment and Cantor Fitzgerald Global Healthcare Conferences

Business Wire | September 3, 2020

ScPharma inks supply agreement with West Pharma

ScPharmaceuticals (SCPH) perks 10% premarket after entering into a supply agreement with West Pharmaceutical Services (WST), pursuant to which the Company has agreed to purchase the SmartDose drug delivery system developed by West (the Product).Under the terms of the Agreement, West will provide with 100% of the Company’s requirements for the Product...

Seeking Alpha | August 21, 2020

scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals announced the FDA has accepted for review the company’s NDA resubmission for FUROSCIX® and assigned a PDUFA date of Dec 30, 2020.

Business Wire | July 27, 2020

scPharmaceuticals Appoints Sara Bonstein to Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals announced the appointment of Sara Bonstein to its Board of Directors.

Business Wire | July 10, 2020

Read More 'SCPH' Stories Here

SCPH Price Returns

1-mo -2.35%
3-mo 5.94%
6-mo 8.84%
1-year 99.54%
3-year -43.97%
5-year N/A
YTD 54.42%
2019 50.53%
2018 -68.90%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7501 seconds.